Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland

Journal of Medical Microbiology

Volumn 64, Issue 6, 2015, Pages 610-619

  Szweda, Piotr ^a   Gucwa, Katarzyna ^a   Romanowska, Ewa ^b   Dzierżanowska Fangrat, Katarzyna ^b   Naumiuk, Łukasz ^c   Brillowska Dąbrowska, Anna ^a   Wojciechowska Koszko, Iwona ^d   Milewski, Sławomir ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; CARRIER PROTEIN; CYTOCHROME P450; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CONTROLLED STUDY; CROSS RESISTANCE; GENE SEQUENCE; NONHUMAN; POLAND; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; CANDIDIASIS; DNA SEQUENCE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; POLYMERASE CHAIN REACTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA GLABRATA; CANDIDIASIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; HOSPITALS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; POLAND; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84935145369     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000062     Document Type: Article

References (35)

1. Arendrup, M. C. (2010). Epidemiology of invasive candidiasis. Curr Opin Crit Care 16, 445–452.
2. Berila, N. & Subik, J. (2010). Molecular analysis of Candida glabrata clinical isolates. Mycopathologia 170, 99–105.
3. Berila, N., Borecka, S., Dzugasova, V., Bojnansky, J. & Subik, J. (2009). Mutations in the CgPDR1 and CgERG11 genes in azoleresistant Candida glabrata clinical isolates from Slovakia. Int J Antimicrob Agents 33, 574–578.
4. Chavanet, P., Lopez, J., Grappin, M., Bonnin, A., Duong, M., Waldner, A., Buisson, M., Camerlynck, P. & Portier, H. (1994). Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 8, 945–950.
5. CLSI (2012). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th informational supplement M27S4. Wayne, PA: Clinical Laboratory Standards Institute.
6. Costa, C., Nunes, J., Henriques, A., Mira, N. P., Nakayama, H., Chibana, H. & Teixeira, M. C. (2014). Candida glabrata drug: H+ antiporter CgTpo3 (ORF CAGL0I10384g): role in azole drug resistance and polyamine homeostasis. J Antimicrob Chemother 69, 1767–1776.
7. Dzierżanowska-Fangrat, K., Romanowska, E., GryniewiczKwiatkowska, O., Migdał, M., Witulska, K., Ryżko, J., Kaliciński, P., Książyk, J., Nadkowska, P. & Dzierzanowska, D. (2014). Candidaemia in a Polish tertiary paediatric hospital, 2000 to 2010. Mycoses 57, 105–109.
8. Edlind, T. D. & Katiyar, S. K. (2010). Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother 54, 4733–4738.
9. Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P. & Sanglard, D. (2011). Loss of mitochondrial functions associated with azole resistance in Candida glabrata results in enhanced virulence in mice. Antimicrob Agents Chemother 55, 1852–1860.
10. Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., ArthingtonSkaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W. & other authors (2004). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42, 1519–1527.
11. Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G., Kelly, D. E. & Kelly, S. L. (2012). Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother 56, 4223–4232.
12. Jabra-Rizk, M. A. (2006). Fungal infections and drug resistance. Emerg Med & Crit Care Rev 2, 38–41.
13. Kaur, R., Castaño, I. & Cormack, B. P. (2004). Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother 48, 1600–1613.
14. Kaur, R., Domergue, R., Zupancic, M. L. & Cormack, B. P. (2005). A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 8, 378–384.
15. Lass-Flörl, C. (2009). The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52, 197–205.
16. DDCT method. Methods 25, 402–408.
17. Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V., Van Broeckhoven, C., Fay, S. & Mose-Larsen, P. (1997). Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 41, 2229–2237.
18. Morio, F., Loge, C., Besse, B., Hennequin, C. & Le Pape, P. (2010). Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66, 373–384.
19. Olchawa, A., Krawczyk, B. & Brillowska-Dabrowska, A. (2013). New PCR test for detection of Candida glabrata based on the molecular target chosen by the RAPD technique. Pol J Microbiol 62, 81–84.
20. Papon, N., Courdavault, V., Clastre, M. & Bennett, R. J. (2013). Emerging and emerged pathogenic Candida species: beyond the Candida albicans paradigm. PLoS Pathog 9, e1003550. .
21. Paul, S., Bair, T. B. & Moye-Rowley, W. S. (2014). Identification of genomic binding sites for Candida glabrata Pdr1 transcription factor in wild-type and r0 cells. Antimicrob Agents Chemother 58, 6904–6912.
22. Pfaller, M. A. & Diekema, D. J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133–163.
23. Pfaller, M. A. & Diekema, D. J. (2010). Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36, 1–53.
24. Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. & Diekema, D. J. (2002). In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46, 3518–3521.
25. Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W. & Ling, T. A. (2010). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48, 1366–1377.
26. Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N. & Castanheira, M. (2013). Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51, 2571–2581.
27. Prażyńska, M. & Gospodarek, E. (2014). In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation. Mycopathologia 177, 19–27.
28. Rodrigues, C. F., Silva, S. & Henriques, M. (2014). Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis 33, 673–688.
29. Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A. & Bille, J. (1999). The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 43, 2753–2765.
30. Sanglard, D., Ischer, F. & Bille, J. (2001). Role of ATP-bindingcassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 45, 1174–1183.
31. Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R. & Fadda, G. (2005). Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49, 668–679.
32. Santhanam, J., Nazmiah, N. & Aziz, M. N. (2013). Species distribution and antifungal susceptibility patterns of Candida species: is low susceptibility to itraconazole a trend in Malaysia? Med J Malaysia 68, 343–347.
33. Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W. & Azeredo, J. (2012). Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev 36, 288–305.
34. Szweda, P., Gucwa, K., Naumiuk, L., Romanowska, E., DzierzanowskaFangrat, K., Brillowska-Dabrowska, A., Wojciechowska-Koszko, I. & Milewski, S. (2014). Evaluation of possibilities in identification and susceptibility testing for Candida glabrata clinical isolates with the Integral System Yeast Plus (ISYP). Acta Microbiol Immunol Hung 61, 161–172.
35. Tscherner, M., Schwarzmüller, T. & Kuchler, K. (2011). Pathogenesis and antifungal drug resistance of the human fungal pathogen Candida glabrata. Pharmaceuticals 4, 169–186.